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Aim: Previous studies on outcome after transcatheter aortic valve implantation
(TAVI) have focused on the ﬁrst 30 days as well as ﬁrst year after the procedure.
Recently new left bundle branch block (LBBB) has been discussed to potentially have
a negative impact on long-term outcome. This study aimed at deﬁnition of the long-
term outcome up to 5 years after TAVI as well as the impact of new LBBB or need for
pacemaker implantation on outcome.
Methods: 376 consecutive patients with symptomatic aortic stenosis were prospec-
tively included. 205 patients were treated with a CoreValve prosthesis and 171
patients with an Edwards Sapien prosthesis. 167 patients developed a new LBBB or
needed a new pacemaker, in 209 patients neither a new LBBB was observed nor a new
pacemaker was required. Patients were followed-up on a yearly basis.
Results: Survival at 1 year follow-up was 81%, at two-year follow-up was 72%, at
three year follow-up 67% and at four year follow-up 60%. NHYA functional class
showed a marked improvement from 3.10.5 before TAVI to 1.80.7 at latest
follow-up. Impaired left ventricular function (ejection fraction <40%) before TAVI
was associated with impaired survival at follow-up (p¼0.012). There was no differ-
ence in long-term survival between patients with and without new LBBB or pace-
maker implantation (see ﬁgure).
Conclusion: Survival more than one year after TAVI is good with a yearly mortality
of less than 10%. A new LBBB or pacemaker implantation after TAVI has no negative
impact on long-term survival.C36 JACC VOP-081
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Introduction: Transcatheter aortic valve implantation (TAVI) has been a reliable
treatment modality for high risk patients with severe aortic stenosis (AS). TAVI has
high procedural success rates however some complications can occur during the
procedure. In this study, our aim is to present our experience with TAVI which is
a recently devoloping therapy in our country by demonstrating the clinical charac-
teristics of the patients and the complications related to the procedure.
Methods:We examined one month postprocedural results of 36 (20 women) high risk
patients with severe AS who had undergone TAVI in our clinic between 01 June 2012
and 31 May 2013. CoreValve (Medtronic Inc., Minneapolis, MN) or Edwards Sapien
XT (Edwards Lifesciences, Irvine, CA) bioprosthesis valves were implanted by
transfemoral approach to all parties.
Results: The mean age of the patients was 78.57.6 (range 55-91 years). Related
diseases of the patients and their risk scores are demonstrated in Table 1. Mean aortic
valve area was 0.60.1 cm2, and aortic valve gradients were 75.714.3 mmHg
(maximal) and 49.38.8 mmHg (mean). Femoral arterial access was achieved by
surgical cut down in 29 patients, and percutaneously (Prostar XL) in 7 patients (Table
2). Complications related to the procedure are demonstrated in Table 3. Two patients
(%5,6) had malapposition of bioprotesis into left ventricle and paravalvular aortic
regurgitation (AR) during the procedure requiring a second valve (CoreValve)
implantation. One patient had cardiac tamponade and treated with pericardiosentesis.
Vascular complication of femoral artery occurred in 5 (%13,9) of the patients
(Percutaneously Prostar XL was used in 3, and surgical cut down in 2 of patients).
Four patients need permanent cardiac pacemaker after TAVI (3 patients treated with
CoreValve, 1 patient with Edwards Sapien). Stroke occured in 1 patient who had
a second CoreValve bioprotesis due to malapposition of the ﬁrst bioprotesis. 3 (8,3%)
of the patients had paravalvular AR after TAVI. Ventricular septal defect which is
a rare complication after TAVI determined in 1 of the patients at the follow up period
treated with Edwards Sapien XT bioprotesis. There was no mortality during the
procedure, and at the 1 month follow-up period. However, at the 3 months of follow-
up 1 (0.02 %) cardiac death occured and 4 (11,1%) deaths observed due to noncardiac
causes (pneumonia, septic shock, renal failure, and head trauma).
Conclusion: TAVI is a reliable treatment modality alternative to surgery with low
incidence of complications, and high success rates for high-risk patients with severe
AS. Our experience is consisted with worldwide results. However there were rela-
tively low number of patients, the requirement of permanent pacemaker in CoreValve
procedures (11.54%) were lower than the reported incidence in literature.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
